Currently out of the existing stock ratings of Laura Prendergast, 39 are a BUY (95.12%), 2 are a HOLD (4.88%).

Laura Prendergast

Work Performance Price Targets & Ratings Chart

Analyst Laura Prendergast, currently employed at STIFEL, carries an average stock price target met ratio of 31.49% that have a potential upside of 23.2% achieved within 49 days. Previously, Laura Prendergast worked at RAYMOND JAMES.

Laura Prendergast’s has documented 81 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on OLMA, Olema Pharmaceuticals at 14-Sep-2026.

Wall Street Analyst Laura Prendergast

Analyst best performing recommendations are on ERAS (ERASCA).
The best stock recommendation documented was for ERAS (ERASCA) at 1/12/2026. The price target of $10 was fulfilled within 9 days with a profit of $3.77 (60.51%) receiving and performance score of 67.24.

Average potential price target upside

BDTX Black Diamond Therapeutics COGT Cogent Biosciences ERAS Erasca MURA Mural Oncology plc NUVL Nuvalent RVMD Revolution Medicines TNGX Tango Therapeutics NKTX Nkarta OLMA Olema Pharmaceuticals FHTX Foghorn Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 22-Nov-2023

$11

$9.29 (543.27%)

$10

5 months 28 days ago
(29-Apr-2026)

0/13 (0%)

$8.43 (328.02%)

Buy Since 30-Sep-2025

$7

$5.12 (272.34%)

$6

7 months 4 days ago
(23-Mar-2026)

0/2 (0%)

$4.85 (225.58%)

Buy Since 12-Sep-2023

$14

$12.29 (718.71%)

$16

7 months 10 days ago
(17-Mar-2026)

0/10 (0%)

$11.77 (527.80%)

Buy Since 18-Nov-2025

$8

$6.29 (367.84%)

$9

9 months 11 days ago
(16-Jan-2026)

0/2 (0%)

$5.44 (212.50%)

Buy Since 14-Dec-2023

10 months 23 days ago
(04-Dec-2025)

1/6 (16.67%)

$5.12 (177.78%)

83

Show more analysts

Please expand the browser size to see the chart

Which stock is Laura Prendergast most bullish on?

Potential upside of $43.01 has been obtained for RVMD (REVOLUTION MEDICINES)

Which stock is Laura Prendergast most reserved on?

Potential downside of $11.04 has been obtained for NUVL (NUVALENT)

What Year was the first public recommendation made by Laura Prendergast?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?